Treatment options for Ankylosing Spondylitis (AS) are still limited. The T helper cell 17 (Th17) pathway has emerged as a major driver of disease pathogenesis and a good treatment target. Janus kinases (JAK) are key transducers of cytokine signals in Th17 cells and therefore promising targets for the treatment of AS. Here we investigate the therapeutic potential of four different JAK inhibitors on cells derived from AS patients and healthy controls, cultured in-vitro under Th17-promoting conditions. Levels of IL-17A, IL-17F, IL-22, GM-CSF and IFNγ were assessed by ELISA and inhibitory effects were investigated with Phosphoflow. JAK1/2/3 and TYK2 were silenced in CD4+ T cells with siRNA and effects analyzed by ELISA (IL-17A, IL-17F and IL-22), Western Blot, qPCR and Phosphoflow. In-vitro inhibition of CD4+ T lymphocyte production of multiple Th17 cytokines (IL-17A, IL-17F and IL-22) was achieved with JAK inhibitors of differing specificity, as well as by silencing of JAK1-3 and Tyk2, without impacting on cell viability or proliferation. Our preclinical data suggest JAK inhibitors as promising candidates for therapeutic trials in AS, since they can inhibit multiple Th17 cytokines simultaneously. Improved targeting of TYK2 or other JAK isoforms may confer tailored effects on Th17 responses in AS.
JAK inhibitors inhibit IL-17A production by established Th17 cells and by synovial fluid CD4+
T cells from AS/SPA patients. Addition of the inhibitors in-vitro also reduced IL-17A responses from established Th17 cell lines from AS patients (after 6 days of Th17-promoting conditions, Fig. 2a ). Figure 2b shows that JAK inhibitors also effectively reduced IL-17A secretion by SPA synovial CD4+ T cells demonstrating effects on joint derived cells.
HC (n = 26)
AS (n = 52) PSA (n = 16) RA (n = 18) age, years (median and range) 40 Small molecule JAK inhibitors have broad inhibitory actions on STAT phosphorylation. We next analysed STAT phosphorylation in AS patient-derived PBMC upon stimulation with IL-6 (reported to signal through JAK1/2 -STAT1/3), Interferon α (IFNα; JAK1/TYK2 -STAT1/5), IL-7 (JAK1/3 -STAT5) and GM-CSF (JAK2 -STAT5), in the presence of Tofa, Ruxo, Bari and CEP ( Fig. 3a-d and Supplementary Table S2 ). Following IL-6 stimulation, Tofa, Ruxo, Bari and CEP all inhibited STAT1 phosphorylation, but STAT3 phosphorylation was only modestly reduced by Tofa and CEP ( Fig. 3a ). Following IFNα stimulation signaling via STAT1 and STAT5 was equally affected by all inhibitors (Fig. 3b ). IL-7-mediated STAT5 phosphorylation was most profoundly reduced by Tofa, less so by Bari, Ruxo and CEP ( Fig. 3c ). GM-CSF induced STAT5 phosphorylation (thought to be mediated via JAK2) was not significantly affected by any inhibitor (Fig. 3d ). Thus the different inhibitors have broad but distinct inhibitory effects on phosphorylation of STAT1, 3 and 5 in our primary patient-derived cell-based assays.
siRNA-mediated silencing of JAK1 and 3 and TYK2 inhibits type 17 cytokine responses. In order to delineate the roles of the different JAK subtypes on "type 17" cytokine production we next determined the effects of siRNA-mediated silencing of JAK 1-3 on Th17 responses in HC CD4+ T cells. We also silenced TYK2, as we had no specific TYK2 inhibitor included in our experiments so far. Efficient transfection and knock-down in HC CD4+ T cells was confirmed using labelled siRNA, Western Blot, flow cytometry and quantitative PCR (qPCR; Supplementary Fig. S4b-e ). Targeting JAK1 or JAK3 inhibited IL-17A and IL-17F secretion, and JAK3 silencing additionally reduced IL-22 secretion from HC CD4+ T cells cultured under Th17-promoting conditions for 3 days in-vitro ( Fig. 4a ). TYK2 silencing also significantly reduced IL-17A, IL-17F and IL-22 secretion (p = 0.021/0.022/0.021, Fig. 4b ), which was confirmed for IL-17A and IL-17F by qPCR ( Supplementary  Fig. S2f ). siRNA-mediated silencing of JAK2 had no significant effect in this assay ( Fig. 4a ). Subsequently we examined the effects of siRNA-mediated silencing of JAK1, JAK2 and TYK2 on STAT phosphorylation following IL-6 (reported to signal through JAK1/2 -STAT1/3) and IFNα (JAK1/TYK2 -STAT1/5) stimulation of HC CD4+ T cells, in order to clarify which JAK was the most promising target to interfere with Th17 maintenance and polarization. IFNα (effects thought to be mediated by JAK1/TYK2 and STAT1/5) was used as a surrogate for TYK2 specific signaling as IL-23 stimulation required preactivation of human CD4+ T cells for 5 days. Figure 4c shows that TYK2 silencing indeed significantly inhibited STAT5 phosphorylation following IFNα stimulation as with Tofa treatment (p = 0.003 and 0.042). IL-6-induced phosphorylation of STAT3 was significantly reduced by JAK2 silencing (p = 0.002, Fig. 4d ). STAT1 phosphorylation upon IL-6 stimulation was significantly reduced by JAK1 and JAK2 silencing (p = 0.003 and 0.002, Supplementary Fig. S4h ). Combination of JAK1 and JAK2 silencing showed an additive effect on the phosphorylation of STAT3 and 1 upon IL-6 stimulation. 
Discussion
We here describe potent in-vitro inhibition of CD4+ T cell production of three important "type 17" cytokines, IL-17A, IL-17F and IL-22, using both small molecule JAK inhibitors and siRNA-mediated gene silencing. Both approaches were effective for CD4+ T cells derived from patients with Ankylosing Spondylitis, Psoriatic Arthritis, Rheumatoid Arthritis as well as healthy controls. Our data strongly reinforce the concept that compared to recombinant antibodies, which target only one or two cytokines at a time, a major advantage of JAK inhibition lies in the simultaneous inhibition of production of multiple Th17-related cytokines. As well as inhibiting IL-17F and IL-22, we here show additional inhibitory effects on GM-CSF production for Tofacitinib (JAK3 > JAK1/2) and CEP-33779 (JAK2) in AS CD4+ T cells. GM-CSF is likely an important pro-inflammatory cytokine in multiple inflammatory diseases including AS [23] [24] [25] . The moderate effects of the inhibitors on GM-CSF could possibly be attributed to the fact that GM-CSF single-producing lymphocytes may be more resistant to manipulation than other Th cell subsets, and/or that GM-CSF/IL-17A double producers contribute only modestly to overall GM-CSF production. Investigation of newer and more specific JAK inhibitors with regard to GM-CSF production by Th17 cells seems rational.
Another interesting aspect requiring more detailed investigation is the interference of JAK inhibition with "type 17" cytokine secretion from KIR3DL2+ (killer cell immunoglobulin like receptor, three Ig domains and long cytoplasmic tail 2) Th17 cells. These cells are enriched in HLA (human leucocyte antigen)-B27-positive SPA patients and contain the majority of IL-17A-producing CD4+ T cells 6 . These cells express higher levels of IL-23 receptor and upon binding of HLA-B27 heavy chain dimers produce increased amounts of IL-17A. The detailed effects of JAK inhibition on this KIR3DL2-B27 heavy chain dimer-induced IL-17A secretion remain to be investigated in another study.
Our data further suggest that, at least in our assays on primary patient-derived cells, current JAK inhibitors are only moderately selective for particular JAK family members and functionally target multiple cytokine pathways. One example for this moderate in-vitro selectivity is the fact, that CEP, with claimed 40-fold selectivity for JAK2 against JAK1, effectively blocks IFNα signaling in our assays, which is supposed to rely on JAK1 and TYK2. On the other hand CEP, as well as the other inhibitors, does not seem to block GM-CSF-induced STAT5 phosphorylation, which is JAK2-dependent. This could be explained by the fact that monocytes from patients with autoimmune disease show sustained STAT5 phosphorylation upon GM-CSF stimulation (greater than 24 h) 26 . This phosphorylation was found to be resistant to JAK2/3 inhibition by AG490, another small molecule inhibitor of JAK. These data suggest that STAT5 phosphorylation is not purely dependent on kinase activity, but could rather depend on mechanisms of dephosphorylation and recycling or degradation. JAK2 silencing on the contrary did lower but not significantly reduce IL-17F and IL-22 secretion. This can be explained by the smaller number of experiments (n = 3 compared to n = 7 for JAK1) and the relatively small population of IL-23 receptor-positive CD4+ T cells, in which JAK2 silencing related effects might be overridden by IL-2. The specific effects of JAK inhibition on IL-23-induced STAT3 phosphorylation could not be examined in this study, as there was no robust shift if Il-23 was used on freshly isolated PBMC. This may be because IL-23-mediated STAT3 phosphorylation requires preactivation of PBMCs via CD3 and CD28 for 5 days or has to be examined in an IL-23 receptor expressing T cell line (e.g. kit225) 22, 27 . IL-6 mediated phosphorylation of STAT3 was only modestly affected by small molecule inhibitors of JAK. This seems controversial, as STAT3 phosphorylation is the hallmark of IL-6 signaling 28 . However, it has been shown previously that IL-6 induced STAT1 phosphorylation is more sensitive to JAK inhibition than STAT3 phosphorylation and that this effect is dose dependent for Tofa. The dose used in our study is lower than the one previously reported to robustly inhibit STAT3 phosphorylation in human CD4+ T cells 18 . The observation that the effect of JAK inhibitors on Th17 cytokine secretion is mainly independent of IL-23 in our study could be explained by the relatively low percentage of IL-23R positive cells. As IL-2, predominantly signaling through JAK1 and JAK3, can expand established Th17 cells and induce IL-17 secretion from human PBMC, it is not surprising, that Tofa has a robust inhibitory effect on Th17 cytokine release in our assay 29 . Nevertheless our data showing robust inhibition of multiple Th17 cytokines (IL-17A, IL-17F and IL-22) under Th17-promoting conditions strongly support further clinical trials of JAK inhibitors in AS/SPA and other Th17-driven inflammatory diseases.
Surprisingly the adverse clinical effects of JAK inhibitors, which are mainly derived from clinical trials and from real world experience of Tofacitinib, have been relatively limited even though targeting multiple cytokine pathways 12 . Malignancy and infections are the major adverse effects observed with these inhibitors, but changes in lipid and serum transaminase levels, cytopenias, and a reduction of the glomerular filtration rate occur as well 12 . Reactivation of varicella zoster virus is one specific adverse effect of JAK inhibition; however disseminative disease is rare 30 . In regard of JAK selectivity sparing of JAK2 might avoid afore mentioned cytopenias. Reduced activity on JAK1 might ameliorate the effect of such inhibitors on antiviral responses, especially through Natural Killer cells 12 . As TYK2 is also involved in IL-10 and type I Interferon signaling, a selective TYK2 inhibitor might confer a risk for reduced intrinsic anti-inflammatory function and increased infections 12, 31 . However, reports on human TYK2 deficiency show a less severe immunodeficiency phenotype compared to JAK3 deficiency 32, 33 . So far safety profiles of JAK inhibitors cannot be accurately derived from the reported in-vitro function of the designated JAK. Long term observations and individual clinical trials will have to be undertaken to prove the superiority of selective inhibitors.
Although we were not able to test a small molecule inhibitor specific for TYK2, the efficacy of siRNA-mediated TYK2 silencing on Th17-associated cytokine secretion supports strategies of TYK2 inhibition for the treatment of AS and other Th17-driven diseases (despite the above mentioned caveats and the observed discrepancy for IL-22 in protein versus messenger RNA level). Recent studies comparing human cell and tissue transcriptomes with proteomes have found that agreement between mRNA and protein levels occurs only in about 40%, with differing translational rates and posttranslational modifications accounting for these differences 34 . Despite difficulties encountered due to the conserved nature of the kinase domain, selective TYK2 inhibitors and novel approaches targeting the pseudokinase domain show promise 35, 36 . Alternative pathways of targeting TYK2 by inhibitory peptides have also been employed 37 . Our silencing experiments also suggest that JAK1 and JAK2 might be effective targets for interference with Th17 responses. Baricitinib is a moderately JAK1-specific inhibitor that has already been approved for RA treatment in the USA and Europe 38 .
One further advantage of JAK inhibitors in regard to targeting multiple cytokine pathways might be an effect on the changes in bone metabolism observed in AS, namely syndesmophyte formation and bony ankylosis. Tofacitinib has been reported to inhibit both inflammation and new bone formation in murine Spondyloarthritis 39 . A current clinical trial of Tofacitinib in AS patients provides the first direct evidence that JAK inhibition might also ameliorate bone proliferation in humans 17 .
In summary our in-vitro data using patient-derived cells show effects of JAK inhibition on multiple "type 17" inflammatory cytokines in SPA, and strongly support further clinical trials of multiple JAK inhibitors of varying specificity in AS/SPA and other Th17-driven inflammatory diseases. Inhibitors. Tofacitinib, Baricitinib, Ruxolitinib, CEP-33779 and Bayer-18 were purchased from Selleckchem, CaymanChemical and Synkinase (reconstituted at 50 mM in DMSO and frozen in aliquots) and used at concentrations and durations described in Supplementary Table S1 immediately upon thawing. Cell viability and proliferation assessment. CD4+ T cells were labeled with 5 µM CFSE (Carboxyfluorescein succinimidyl ester; Molecular Probes) and cultured as above. Anti-Annexin V and 7-AAD (7-Aminoactinomycin D; Biolegend) staining was used for viability assessment after three days of in-vitro culture as above. Further information available in online Supplementary Material and Methods.
Patients and Methods

Cell Purification and
Intracellular Flow Cytometry.
Freshly isolated PBMC or CD4+ T cells were stimulated and stained for intracellular flow cytometry of STAT and JAK as described in online Supplementary Material and Methods and Supplementary Table S2 .
Silencing of JAK1, JAK2, JAK3 and TYK2. CD4+ T cells were electroporated with 2 to 5 µM of the respective siRNA (Eurogentec and ThermoFisher Scientific) using the Neon ™ Transfection System (ThermoFisher Scientific). See also online Supplementary Material and Methods and Supplementary Table S3 .
Statistical analysis.
Between-group differences were determined as indicated in the figure legends using paired t-Test, repeated measures 1-way and 2-way ANOVA followed by Dunnett's or Bonferroni's method for multiple comparisons (GraphPad Prism software version 5). P values less than 0.05 were considered statistically significant.
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